Rhizen Pharmaceuticals and Incozen Therapeutics have synthesized new cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, Alzheimer's disease, pulmonary fibrosis, inflammatory disorders, psoriasis and rheumatoid arthritis, among other disorders.